Trodelvy fails PhI­II lung can­cer study in blow to Gilead’s ADC ex­pan­sion plans

Gilead’s an­ti­body-drug con­ju­gate Trodelvy failed to sig­nif­i­cant­ly ex­tend sur­vival in a late-stage lung can­cer study, the phar­ma com­pa­ny said Mon­day morn­ing.

The Phase III EVOKE …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.